Shanghai Pharmaceuticals Holding (601607.SH): Ursodeoxycholic Acid Capsules Approved for Production.

Shanghai Pharmaceuticals Holding (601607.SH) announced that its subsidiary Changzhou Pharmaceutical Factory Co., Ltd. (hereinafter referred to as "Changzhou Pharmaceutical Factory") recently received a "Drug Registration Certificate" (Certificate No.: 2025S00209) from the National Medical Products Administration for its ursodeoxycholic acid capsules (250mg; hereinafter referred to as "the drug"), granting approval for production. Ursodeoxycholic acid capsules are mainly used to treat gallbladder cholesterol stones that are X-ray penetrable, with normal gallbladder contraction function; biliary stasis liver disease (such as primary biliary cirrhosis); and bile reflux gastritis. As of the announcement date, the company has invested approximately RMB 12.15 million in research and development expenses for this drug.